Lisa D. Beilke, MSPH, PhD, DABT
President/CEO
Classically trained toxicologist with over 20 years in the biotechnology industry with a specialty in Computational Toxicology.
Dr. Beilke is a board-certified toxicologist with over 20 years of experience working in various fields of toxicology in support of small molecule therapeutics. She has worked for small contract laboratories, startup biotechs, as well as large pharma (Pfizer, Gilead). She earned her PhD in Pharmacology & Toxicology from the University of Arizona, as well as her BS and MS (Public Health/Toxicology) degrees from San Diego State University. Dr. Beilke has been an independent consultant with Toxicology Solutions, Inc. since its inception in 2013, and has focused on providing toxicology services to the pharmaceutical industry, with a specialty in in silico toxicity predictions for potential genotoxic impurities and risk assessment. As a consultant, Dr. Beilke has worked with clients on various therapeutic areas (oncology, metabolic diseases, cardiovascular, etc.) and compound types (e.g., peptides, polymers, antibodies, dye conjugates, etc.) to help assess risk and characterize safety. Overall program goals are also incorporated into strategic decision making to anticipate obstacles and difficulties to ensure goals are met.
Dr. Beilke has a long history of involvement with various toxicology organizations. She has been a member of the American College of Toxicology (ACT) since 1999 and has served on the Education (2009-2011) and Finance Committees (2011-2014), Councilor (2016-2018), and Nominating Committee (2020-2021) and was presented with the Young Investigator award in 2013. She is also on the Editorial Board of the International Journal of Toxicology (2013-present). She is a full member of the Society of Toxicology (SOT), where she co-developed a new Specialty Section: Computational Toxicology Specialty Section (CTSS).
Archie W.
Thurston Jr., PhD
Archie W. Thurston Jr., PhD
Chief Operating Officer
25+ yrs of Pharmaceutical Research and Development Experience in Drug Metabolism / Pharmacokinetics predominantly in “large pharma”
Prior to consulting, Archie worked 25 years in the pharmaceutical industry starting at Rhone-Poulenc Rorer as a research scientist where he began applying in vitro models to predicting in vivo parameters in a drug discovery setting. Later, Archie moved to Solvay Pharmaceuticals where he built a group focused on developing drug metabolism methodologies to support the ADME drug discovery effort and was then promoted into a leadership role. Later, Archie moved to Pfizer Global Research and Development where he continued to develop his scientific experiences as a Director of a PDM (pharmacokinetics, dynamics and metabolism) group providing ADME support to drug discovery research programs for topical and inhalation drug projects. After Pfizer, Archie managed the PDM (Pharmacokinetics / Drug Metabolism) Group at Seventh Wave Laboratories where managed bioanalytical (both non-GLP and GLP), PK/TK (non-GLP and GLP), and drug metabolism groups. While managing these groups, Archie served as a Principal Investigator for both preclinical PK/TK and clinical PK studies in support of both small molecule and large molecule programs. In October of 2016, Archie started ADME Solutions, Inc. and began independent consulting.
Charlotte A. Mintie, PhD, DABT
Charlotte A. Mintie, PhD, DABT
PrincipAl Consultant
Dr. Mintie is a board-certified toxicologist. Prior to TSI, Dr. Mintie had 5 years of experience in Drug Development at a Contract Research Organization (CRO). Dr. Mintie obtained her PhD from the University of Wisconsin-Madison in Comparative Biomedical Sciences and a BS at the University of Wisconsin-River Falls. With nearly 3.5 years as a Toxicology Study Director, Dr. Mintie was responsible for overseeing Toxicology studies (large and small molecule) in multiple animal species via various routes of administration. Prior to obtaining her doctoral degree, Dr. Mintie was employed as a Study Technician in the DMPK group at the same CRO, where she learned the technical skills to appropriately execute exploratory and DMPK study designs.
At TSI, Dr. Mintie provides toxicology program support for a variety of therapeutic areas and compound types, as well as supports computational tox, risk assessment, and toxicokinetic analysis. Dr. Mintie is a Phoenix WinNonlin 8.3 Certara Certified NCA Analyst.
Dr. Mintie is currently a member of the American College of Toxicology (ACT) and the Society of Toxicology (SOT).